Cochlear appoints experienced industry executive to its Board

Latest News

Cochlear (ASX:COH) has announced the appointment of Abbas Hussain to its Board.

Mr Hussain has worked in the pharmaceutical industry for 30 years. In his most recent role, Mr Hussain was global president of Pharmaceuticals at GSK, where he had overall responsibility for the company’s business and led operations supporting commercial infrastructure, including medical, finance, human resources, IT, legal and communications.

Mr Hussain managed GSK’s global pharmaceuticals and vaccine business across 150 markets including the US, Europe, Japan and emerging markets.

He also has experience in the areas of research and development, quality control and capital investments.

According to Cochlear Chairman, Mr Rick Holliday-Smith, “Given his knowledge in pharmaceuticals, Abbas will bring experience and expertise to prioritisation of business development and growth opportunities across unique and diverse markets.

"Abbas is well-equipped to provide valuable strategic insight and has demonstrated strong values in customer focus which is intrinsic to Cochlear’s strategic platforms. His career has been spent at the forefront of emerging markets and his deep experience in China and India will be invaluable as these represent key emerging markets for Cochlear.”

Mr Hussain is currently a Non-Executive Director of CSL and Immunocore. He is also a senior advisor to CellResearch Corp and C-Bridge Capital. Mr Hussain resides in the United Kingdom.